A three-year sponsorship of a new scientific post at the Government's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) that demonstrates the pharmaceutical industry's continued commitment to the centre's objectives has been announced by the Association of the British Pharmaceutical Industry (ABPI).
While the industry is providing the sponsorship, the holder of the post will be a full employee of the centre and report to its chief executive.
UK-based pharmaceutical companies currently spend around £300 million a year on technologies that have directly or indirectly replaced the use of Animals and Medicines Research, and warmly welcomed the Government's announcement last year of the establishment of the NC3Rs.
The ABPI fully supports the concept of reducing, refining and replacing the use of Animals and Medicines Research - it is not only a question of being humane but it also ensures high quality research and makes good business sense to reduce costs," said Dr Philip Wright, the ABPI's Director of Science and Technology.
The industry's sponsorship of the new post was also welcomed by NC3Rs Chief Executive Dr Vicky Robinson, who said: "It is clearly important that the centre works closely with the pharmaceutical industry to progress the 3Rs, and this new post will help us to achieve that objective."
The initial primary objectives of the new job are to:
Companies participating in the post's sponsorship are GlaxoSmithKline, Astra Zeneca, Pfizer, Lilly, Merck Sharp & Dohme, Novartis, Huntingdon Life Sciences and Sanofi-Aventis.
The NC3Rs provides a focus for the promotion, development and implementation of the 3Rs in animal research, and replaces and builds upon the Medical Research Council's Centre for Best Practice for Animals in Research (CBPAR). It brings together stakeholders in the 3Rs in government, academia, industry and animal welfare organisations to facilitate the exchange of information and ideas, and the translation of research findings into practice that will benefit both animals and research.
For further information, please contact: ABPI Press Office 020 7747 1410